(Carbidopa + levodopa) is a small molecule commercialized by Amneal Pharmaceuticals, with a leading Pre-Registration program in Parkinson’s Disease. According to Globaldata, it is involved in 5 clinical trials, which were completed. GlobalData uses proprietary data and analytics to provide a complete picture of (Carbidopa + levodopa)’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

The revenue for (Carbidopa + levodopa) is expected to reach an annual total of $179 mn by 2032 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

(Carbidopa + levodopa) Overview

IPX-203 is an extended-release formulation of carbidopa in combination with levodopa is under development for the treatment of Parkinson’s disease. The drug candidate is a small molecule. It is administered through oral route. IPX203 contains two different drugs called levodopa and carbidopa in one capsule.Levodopa acts by targeting dopaminergic receptors and carbidopa acts by targeting DOPA decarboxylase. It is developed based on controlled-release delivery technology. 

Amneal Pharmaceuticals Overview

Amneal Pharmaceuticals (Amneal), formerly Amneal Pharmaceuticals, is a pharmaceutical company that develops, manufactures, markets and distribute pharmaceutical drug. It offering products includes generic and specialty pharmaceutical products. The company also offers product such as Activella, Albenza, Dexedrine, Nizatidine Oral Solution and Pyridiu in the area of oncology, inflammation and pain, central nervous system disorders, endocrinology and parasitic infections. Amneal offers products in various dosage forms such as oral solids and liquids, injectables, topicals, creams and ointments, transdermals, inhalation, ophthalmic and otic liquids and other device driven products. The company has operational presence in India, Switzerland, Ireland and the U.K. Amneal is headquartered in Bridgewater, New Jersey, the US.

The company reported revenues of (US Dollars) US$2,093.7 million for the fiscal year ended December 2021 (FY2021), an increase of 5.1% over FY2020. In FY2021, the company’s operating margin was 7.3%, compared to an operating margin of 4.6% in FY2020. In FY2021, the company recorded a net margin of 0.5%, compared to a net margin of 4.6% in FY2020. The company reported revenues of US$545.6 million for the third quarter ended September 2022, a decrease of 2.5% over the previous quarter.

For a complete picture of (Carbidopa + levodopa)’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.